A post by @FirstSquawk on X.

Hims & Hers Health's CFO attributed higher third-quarter revenue per subscriber to growing demand for menopause therapies and testosterone testing, according to remarks reported by First Squawk. The company did not disclose specific figures in the cited comments, but the mix shift toward these higher-value offerings signals improving monetization of its existing subscriber base. The development matters because revenue per subscriber is a key gauge of how effectively the telehealth platform can expand average spend without proportionally adding new customers. Investors will watch whether these categories sustain momentum into the fourth quarter and whether they lift overall margins alongside top-line growth.